To this end, therapeutic opportunities may exist in the regulation of TMEM16A function for the treatment of a host of human diseases including cystic fibrosis, asthma, pulmonary hypertension, secretory diarrhoea and cancer. Here, ANO1 is linked to pulmonary hypertension.